MX2009002064A - Una composicion farmaceutica para tratar colangiocarcinoma, un metodo para inhibir el crecimiento o invasion del colangiocarcinoma y un metodo para tratamiento de colangiocarcinoma. - Google Patents

Una composicion farmaceutica para tratar colangiocarcinoma, un metodo para inhibir el crecimiento o invasion del colangiocarcinoma y un metodo para tratamiento de colangiocarcinoma.

Info

Publication number
MX2009002064A
MX2009002064A MX2009002064A MX2009002064A MX2009002064A MX 2009002064 A MX2009002064 A MX 2009002064A MX 2009002064 A MX2009002064 A MX 2009002064A MX 2009002064 A MX2009002064 A MX 2009002064A MX 2009002064 A MX2009002064 A MX 2009002064A
Authority
MX
Mexico
Prior art keywords
cholangiocarcinoma
llcam
growth
invasion
treating
Prior art date
Application number
MX2009002064A
Other languages
English (en)
Inventor
Hyo Jeong Hong
Jung-Whoi Lee
Jin Man Kim
Yeon Sung Son
Eung Suck Lee
Original Assignee
Korea Res Inst Of Bioscience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Res Inst Of Bioscience filed Critical Korea Res Inst Of Bioscience
Publication of MX2009002064A publication Critical patent/MX2009002064A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describe en la presente una composición farmacéutica para inhibir el crecimiento o metástasis de colangiocarcinoma, que comprende un inhibidor de la actividad de LICAM o supresor de expresión y un método de tratamiento que utiliza la composición; esto se basa en el descubrimiento de que LICAM se sobreexpresa en colangiocarcinoma y juega un papel importante en el crecimiento y metástasis de colangiocarcinoma y la mortalidad de los pacientes con colangiocarcinoma incrementa a medida que incrementa la velocidad de expresión de LICAM; también, se ha encontrado que los anticuerpos inhibidores de la actividad de LICAM o ARNsi que suprimen la expresión de LICAM, reducen el crecimiento e invasión de células de colangiocarcinoma; los anticuerpos monoclonales de ratón, que reconocen la proteína de LICAM en la superficie celular de colangiocarcinoma y se unen específicamente a los tejidos de colangiocarcinoma, o ARNsi, oligonucleótidos antisentido o ARNsh, pueden ser útiles en el tratamiento de colangiocarcinoma al inhibir el crecimiento, invasión y migración de la célula de colangiocarcinoma.
MX2009002064A 2006-08-23 2007-08-23 Una composicion farmaceutica para tratar colangiocarcinoma, un metodo para inhibir el crecimiento o invasion del colangiocarcinoma y un metodo para tratamiento de colangiocarcinoma. MX2009002064A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20060079969 2006-08-23
KR1020070084868A KR100931976B1 (ko) 2006-08-23 2007-08-23 담도암 치료용 약제학적 조성물 및 이를 이용한 담도암의성장, 전이 억제 및 치료 방법
PCT/KR2007/004046 WO2008023947A1 (en) 2006-08-23 2007-08-23 A pharmaceutical composition for treating cholangiocarcinoma, a method for inhibiting growth or invasion of cholangiocarcinoma and a method for treating cholangiocarcinoma

Publications (1)

Publication Number Publication Date
MX2009002064A true MX2009002064A (es) 2009-06-30

Family

ID=39385312

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009002065A MX2009002065A (es) 2006-08-23 2007-08-23 Una composicion farmaceutica para tratar cancer pulmonar, un metodo para inhibir el crecimiento o invasion de cancer pulmonar y un metodo para tratar cancer pulmonar.
MX2009002064A MX2009002064A (es) 2006-08-23 2007-08-23 Una composicion farmaceutica para tratar colangiocarcinoma, un metodo para inhibir el crecimiento o invasion del colangiocarcinoma y un metodo para tratamiento de colangiocarcinoma.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2009002065A MX2009002065A (es) 2006-08-23 2007-08-23 Una composicion farmaceutica para tratar cancer pulmonar, un metodo para inhibir el crecimiento o invasion de cancer pulmonar y un metodo para tratar cancer pulmonar.

Country Status (10)

Country Link
US (1) US8153122B2 (es)
EP (2) EP2054083B1 (es)
JP (3) JP5923233B2 (es)
KR (2) KR100932698B1 (es)
CN (2) CN101528258A (es)
AU (2) AU2007288620B2 (es)
BR (2) BRPI0715844A2 (es)
CA (2) CA2661669C (es)
MX (2) MX2009002065A (es)
WO (2) WO2008023946A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101528258A (zh) * 2006-08-23 2009-09-09 韩国生命工学研究院 治疗肺癌的药物组合物，抑制肺癌生长或侵入的方法和治疗肺癌的方法
CA2691075C (en) * 2007-06-15 2017-04-11 Daniela Gast Treatment of tumors using specific anti-l1 antibody
MX2010010177A (es) * 2008-03-17 2012-08-23 Regenerx Biopharmaceuticals Fragmentos de beta timosina mejorada.
KR20100060351A (ko) * 2008-11-27 2010-06-07 한국생명공학연구원 Ｌ１ｃａｍ의 활성 또는 발현을 억제하는 물질 및 항암제를포함하는 항암용 조성물
KR101501736B1 (ko) * 2008-12-05 2015-03-12 한국생명공학연구원 인간 및 마우스에서 발현하는 ｌ1ｃａｍ에 특이적으로 결합하는 재조합 단일클론항체 및 그 이용
JP5716257B2 (ja) * 2009-02-06 2015-05-13 国立大学法人 熊本大学 胆管癌特異的糖鎖エピトープを認識するモノクローナル抗体
KR101271964B1 (ko) * 2010-07-08 2013-06-07 강원대학교산학협력단 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법
TW201312117A (zh) * 2011-07-28 2013-03-16 Univ Pennsylvania 用以診斷與漿液相關之腫瘤細胞的症狀及特性的方法及試劑
KR101504039B1 (ko) 2012-11-16 2015-03-19 강원대학교산학협력단 인간 및 마우스 ｌ１ｃａｍ 단백질에 특이적으로 결합하는 항체 및 이의 용도
WO2015042303A1 (en) * 2013-09-18 2015-03-26 Memorial Sloan-Kettering Cancer Center Inhibiting cancer metastasis
AU2015307186A1 (en) * 2014-08-27 2017-04-13 Peptimed, Inc. Anti-tumor compositions and methods
CN104894259A (zh) * 2015-06-01 2015-09-09 北京泱深生物信息技术有限公司 Tex19基因在胆管癌诊断和治疗中的应用
KR101892908B1 (ko) 2015-11-02 2018-08-29 아주대학교산학협력단 글루코코르티코이드계 화합물을 포함하는 비소세포성 폐암 치료용 약학 조성물
US11260062B2 (en) 2015-11-02 2022-03-01 Ajou University Industry-Academic Cooperation Foundation Pharmaceutical composition for treatment of lung cancer comprising glucocorticoid-based compound
KR20190036553A (ko) 2016-08-02 2019-04-04 메모리얼 슬로안 케터링 캔서 센터 전이성 암의 치료 및 전이성 질환에 대한 모델 시스템
KR20180079232A (ko) * 2016-12-30 2018-07-10 강원대학교산학협력단 L1cam 단백질에 특이적으로 결합하는 항체 및 피리미딘 유사체 및/또는 플라틴계 항암제를 포함하는 암의 예방 또는 치료용 약학적 조성물
US11597764B2 (en) 2017-06-15 2023-03-07 Memorial Sloan Kettering Cancer Center Anti-L1-CAM antibodies and uses thereof
WO2020003210A1 (en) 2018-06-29 2020-01-02 Kangwon National University University-Industry Cooperation Foundation Anti-l1cam antibodies and uses thereof
GB201913124D0 (en) 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
GB201913121D0 (en) 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
GB201913122D0 (en) 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
GB201913123D0 (en) 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
CN111053774B (zh) * 2019-12-20 2022-10-11 厦门大学 盐酸他克林在制备治疗胆管癌的药物中的应用
CN112239505B (zh) * 2020-10-13 2022-05-20 上海良润生物医药科技有限公司 重组抗cd171八价抗体及神经来源外泌体的捕获方法
CN114657129B (zh) * 2022-04-11 2023-12-01 中山大学孙逸仙纪念医院 一种胆管癌淋巴结转移动物模型及其构建方法
CN114917348B (zh) * 2022-06-21 2023-08-04 四川大学华西医院 神经粘附因子在制备抑制和标记肝癌细胞转移的试剂中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5872225A (en) 1992-06-26 1999-02-16 Case Western Reserve University Method for characterizing the nucleotide sequence of L1CAM and the nucleotide sequence characterized thereby
EP1172654B1 (en) 2000-07-10 2007-10-31 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Diagnostic method based on the detection of the L1 adhesion molecule for ovarian and endometrial tumors
US20040082847A1 (en) * 2002-10-23 2004-04-29 Mcdermott Kathleen B. System and methods for identifying brain regions supporting language
AU2003286645A1 (en) * 2002-10-24 2004-05-13 The Board Of Trustees Of The University Of Illinois Antibody-mediated induction of tumor cell death
EP1671645A4 (en) 2003-09-04 2007-07-25 Chugai Pharmaceutical Co Ltd REMEDIES AND MEDIUM FOR DETECTING GALLENGIFT CANCER
EP1623995A1 (en) 2004-08-06 2006-02-08 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibitors of L1 and ADAM10 for the treatment of carcinomas
CN101528258A (zh) * 2006-08-23 2009-09-09 韩国生命工学研究院 治疗肺癌的药物组合物，抑制肺癌生长或侵入的方法和治疗肺癌的方法

Also Published As

Publication number Publication date
CA2661669A1 (en) 2008-02-28
CN101605560A (zh) 2009-12-16
BRPI0715845A2 (pt) 2014-11-11
JP2010501548A (ja) 2010-01-21
AU2007288620A1 (en) 2008-02-28
WO2008023946A1 (en) 2008-02-28
US20100196350A1 (en) 2010-08-05
KR100931976B1 (ko) 2009-12-15
EP2054083A1 (en) 2009-05-06
AU2007288619A1 (en) 2008-02-28
MX2009002065A (es) 2009-06-30
KR20080018149A (ko) 2008-02-27
EP2054083A4 (en) 2010-03-24
US8153122B2 (en) 2012-04-10
AU2007288620B2 (en) 2012-08-30
CN101605560B (zh) 2013-06-26
CA2661665A1 (en) 2008-02-28
JP2015007045A (ja) 2015-01-15
JP2010501549A (ja) 2010-01-21
CA2661669C (en) 2017-02-14
KR20080018150A (ko) 2008-02-27
CN101528258A (zh) 2009-09-09
KR100932698B1 (ko) 2009-12-21
BRPI0715844A2 (pt) 2013-11-26
WO2008023947A1 (en) 2008-02-28
EP2051733A1 (en) 2009-04-29
EP2054083B1 (en) 2013-11-27
JP5923233B2 (ja) 2016-05-24

Similar Documents

Publication Publication Date Title
MX2009002064A (es) Una composicion farmaceutica para tratar colangiocarcinoma, un metodo para inhibir el crecimiento o invasion del colangiocarcinoma y un metodo para tratamiento de colangiocarcinoma.
PH12020500203A1 (en) Identification of lkb1 mutation as a predictive boimarker for sensitivity to tor kinase inhibitors
WO2012005550A3 (ko) 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
TN2012000555A1 (en) Antibodies to human gdf8
EA201070611A1 (ru) Ингибиторы человеческой фосфатидилинозитол-3-киназы дельта
WO2012037155A3 (en) Tyrosine kinase inhibitors
MY183661A (en) Treatment of cancer with tor kinase inhibitors
WO2007087113A3 (en) Natural antisense and non-coding rna transcripts as drug targets
EA201171495A1 (ru) Применение ингибиторов сукцинатдегидрогеназы для контроля sclerotinia ssp.
WO2010065671A3 (en) Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
MX343397B (es) Oligonucleotidos antisentido dirigidos contra el factor de crecimiento del tejido conectivo y usos de los mismos.
MX2010005768A (es) Composiciones y métodos para inhibir la activación del arnbc-dependiente de la proteina de la kinasa y la inhibición del crecimiento tumoral.
WO2009009793A3 (en) Inhibitors of akt/pkb with anti-tumor activity
WO2009158432A3 (en) Ang-2 inhibition to treat multiple sclerosis
WO2010123527A3 (en) Use of epidermal growth factor inhibitors in the treatment of viral infection
WO2011127465A3 (en) Ship inhibitors and uses thereof
EA201100874A1 (ru) Соединения для лечения рака
MX2009000359A (es) Metodos paratratar y limitar trastornos fibroticos y queloides.
WO2011127202A3 (en) Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of myc-driven tumor cells
WO2006048877A3 (en) Treatment of b-cell malignancies with fgfr3 inhibitors
EA201490928A1 (ru) Способы лечения острых приступов подагры
WO2008067158A3 (en) METHOD TO PROMOTE HAIR GROWTH AND/OR DELAY OR TREAT HAIR LOSS BY ADMINISTERING A TGF-β ANTAGONIST OR INHIBITOR
EA200970764A1 (ru) Способ лечения расстройств, вызванных пролиферацией клеток, с применением стимуляторов секреции гормона роста
CA2810119C (en) Clec14a inhibitors

Legal Events

Date Code Title Description
FG Grant or registration